Redefining Clostridioides difficile infection antibiotic response and clinical outcomes.

[1]  Krutova Marcela,et al.  How to: Clostridioides difficile infection in children. , 2022, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  E. Kuijper,et al.  European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. , 2021, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  K. Garey,et al.  Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  C. Kelly,et al.  ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections , 2021, The American journal of gastroenterology.

[5]  G. Riou,et al.  Comparison of different modes of antibiotic delivery on gut microbiota depletion efficiency and body composition in mouse , 2020, BMC Microbiology.

[6]  K. Garey,et al.  Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection , 2020, Open forum infectious diseases.

[7]  Junhua Li,et al.  Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing. , 2019, Anaerobe.

[8]  S. Bosis,et al.  Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE) , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  T. Louie,et al.  Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. , 2019, The Lancet. Infectious diseases.

[10]  B. Guery.  Clostridium difficile infection trials: what is the primary endpoint? , 2019, The Lancet. Infectious diseases.

[11]  K. Tateda,et al.  Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan. , 2018, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[12]  K. Carroll,et al.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  V. Anttila,et al.  Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. , 2017, The Lancet. Infectious diseases.

[14]  T. Louie,et al.  Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial , 2017, The Journal of antimicrobial chemotherapy.

[15]  R. Fedorak,et al.  Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection , 2017, Open forum infectious diseases.

[16]  Jeroen Raes,et al.  Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates , 2015, Gut.

[17]  Antonio Ramos,et al.  Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. , 2015, JAMA.

[18]  D. Gerding,et al.  Lack of evidence for an unmet need to treat Clostridium difficile infection in infants aged <2 years: expert recommendations on how to address this issue. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  T. Louie,et al.  Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  C. Donskey,et al.  Defining the Vulnerable Period for Re-Establishment of Clostridium difficile Colonization after Treatment of C. difficile Infection with Oral Vancomycin or Metronidazole , 2013, PloS one.

[21]  Elena Deych,et al.  Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  P. Tamma,et al.  Clostridium difficile Infection in Children: Current State and Unanswered Questions. , 2012, Journal of the Pediatric Infectious Diseases Society.

[23]  D. Gerding,et al.  Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  D. Crook,et al.  Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. , 2012, The Lancet. Infectious diseases.

[25]  Pamela Sears,et al.  Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.

[26]  H. Binder,et al.  Role of colonic short-chain fatty acid transport in diarrhea. , 2010, Annual review of physiology.

[27]  G. Velmahos,et al.  Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. , 2009, Archives of surgery.

[28]  J. Bartlett,et al.  Clinical recognition and diagnosis of Clostridium difficile infection. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  Melinda B Davis,et al.  A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  D. Musher,et al.  Nitazoxanide for the treatment of Clostridium difficile colitis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  C. Sirio,et al.  Fulminant Clostridium difficile: An Underappreciated and Increasing Cause of Death and Complications , 2002, Annals of surgery.

[32]  S. Lewis,et al.  Stool form scale as a useful guide to intestinal transit time. , 1997, Scandinavian journal of gastroenterology.

[33]  D. Gerding,et al.  PROSPECTIVE RANDOMISED TRIAL OF METRONIDAZOLE VERSUS VANCOMYCIN FOR CLOSTRIDIUM-DIFFICILE-ASSOCIATED DIARRHOEA AND COLITIS , 1983, The Lancet.

[34]  Matthew Sims,et al.  Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. , 2017 .